



**Contacts:** Rob Stewart  
Investor Relations  
Tel (949) 480-8300  
Fax (949) 480-8301

**Media Contact:** Adam Handelsman  
President & Founder  
SpecOps Communications  
Tel (212) 518-7721  
[adam@specopscomm.com](mailto:adam@specopscomm.com)

FOR RELEASE  
October 21, 2013

### **ACACIA SUBSIDIARY ENTERS INTO A SETTLEMENT AGREEMENT REGARDING PRESSURIZED METERED DOSE INHALERS**

Newport Beach, Calif. – (BUSINESS WIRE) October 21, 2013 – Acacia Research Corporation (NASDAQ: ACTG) announced today that its Accuhale LLC subsidiary has entered into a settlement agreement regarding pressurized metered dose inhalers with AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca Dunkerque Production SCS and AstraZeneca AB. The agreement resolves litigation that was pending in the United States District Court for the Eastern District of Texas.

### **ABOUT ACACIA RESEARCH CORPORATION**

Acacia Research Corporation's subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue.

Information about Acacia Research Corporation and its subsidiaries is available at and [www.acaciaresearch.com](http://www.acaciaresearch.com).

### ***Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995***

*This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and*

*competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.*